Alleviation of cancer-related symptoms by MR16-1 treatment seems to contribute to the reduction of TNF-α and IL-1β levels rather than the MR16-1 treatment having a direct impact on their levels by the blockade of IL-6 signaling. This evidence concerns the gene IL6 and cancer.